ProShare Advisors LLC Buys 8,462 Shares of HealthEquity, Inc. (NASDAQ:HQY)

ProShare Advisors LLC lifted its stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 42.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,253 shares of the company's stock after purchasing an additional 8,462 shares during the quarter. ProShare Advisors LLC's holdings in HealthEquity were worth $2,711,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in HQY. Arcadia Investment Management Corp MI acquired a new stake in HealthEquity during the 4th quarter worth approximately $26,000. Transce3nd LLC acquired a new stake in HealthEquity during the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC boosted its position in HealthEquity by 34.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 384 shares of the company's stock worth $37,000 after buying an additional 98 shares during the period. UMB Bank n.a. boosted its position in HealthEquity by 65.6% during the 4th quarter. UMB Bank n.a. now owns 414 shares of the company's stock worth $40,000 after buying an additional 164 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ boosted its position in HealthEquity by 1,934.8% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 468 shares of the company's stock worth $45,000 after buying an additional 445 shares during the period. 99.55% of the stock is owned by institutional investors.

Insider Transactions at HealthEquity

In other news, Director Robert W. Selander sold 5,750 shares of the company's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $77.65, for a total value of $446,487.50. Following the completion of the sale, the director now owns 84,969 shares in the company, valued at $6,597,842.85. This represents a 6.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Michael Henry Fiore sold 8,881 shares of the company's stock in a transaction on Friday, April 4th. The stock was sold at an average price of $78.26, for a total transaction of $695,027.06. Following the completion of the sale, the executive vice president now owns 56,655 shares of the company's stock, valued at approximately $4,433,820.30. The trade was a 13.55% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.50% of the company's stock.

HealthEquity Stock Down 1.1%

HQY traded down $1.07 during trading on Friday, hitting $99.01. 908,113 shares of the company's stock were exchanged, compared to its average volume of 806,052. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51. The business's 50 day moving average is $88.03 and its two-hundred day moving average is $97.40. HealthEquity, Inc. has a fifty-two week low of $65.01 and a fifty-two week high of $115.59. The stock has a market cap of $8.56 billion, a P/E ratio of 90.83, a PEG ratio of 1.60 and a beta of 0.45.

Wall Street Analyst Weigh In

Several research firms recently commented on HQY. The Goldman Sachs Group cut their target price on shares of HealthEquity from $107.00 to $94.00 and set a "neutral" rating on the stock in a research report on Thursday, March 27th. Barrington Research reissued an "outperform" rating and issued a $112.00 price target on shares of HealthEquity in a research note on Friday, April 11th. Wells Fargo & Company increased their price target on HealthEquity from $110.00 to $125.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Raymond James raised HealthEquity from an "outperform" rating to a "strong-buy" rating and decreased their price target for the company from $120.00 to $115.00 in a research note on Tuesday, March 25th. Finally, Royal Bank of Canada initiated coverage on shares of HealthEquity in a research report on Thursday. They issued an "outperform" rating and a $112.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $112.33.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.